Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Treatment of Active Ulcerative Colitis (Phase 2, Randomized, Placebo-Controlled)
2014-002981-64Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apremilast in autoimmune colitis (3 arms), sponsored by Celgene Corporation. Primary endpoint: Clinical remission at Week 12 (Total Mayo Score). Started May 2015; status: completed.
02
Drugs
apremilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2014-002981-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002981-64.